Google-backed Isomorphic Labs receives $2.1 billion funding to accelerate AI Drug design

The AI-led drug design and development company, Isomorphic Labs has raised a funding of USD 2.1 billion. The funding round was led by existing investor Thrive Capital and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. This latest round of investment will accelerate the company's evolution from pioneering novel AI models to applying them at scale.    

"We are humbled to have the opportunity to continue to support Isomorphic's mission to solve all disease," said Joshua Kushner, Founder and CEO of Thrive Capital. "Over the past year, our conviction in the team has only deepened as they've made significant progress in building a unified AI drug design engine to define a new age of drug discovery and design."

The new capital will be used for the continued development and deployment of Isomorphic Labs' AI drug design engine (IsoDDE), accelerating and expanding its pipeline of therapeutic programs towards the clinic. Additionally, the funding will support our existing hiring targets by integrating world-class AI, engineering, drug design, and clinical talent across our sites; this global scale is crucial to Isomorphic Labs' long-term vision of applying AI-driven breakthroughs to the most complex biological and medical challenges and addressing the global burden of disease.

"This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development," said Sir Demis Hassabis, Founder and CEO. "Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease."

Isomorphic Labs has developed a number of proprietary breakthrough AI models that together form its unified AI drug design engine that works across multiple therapeutic areas and drug modalities. Isomorphic Labs recently published a subset of the powerful and expansive capabilities of IsoDDE, highlighting its predictive accuracy and introducing new capabilities which bridge the gap between structure prediction and real-world drug discovery. IsoDDE offers a scalable foundation for AI drug design, providing the predictive fidelity required to navigate novel biological systems with unprecedented accuracy.